Ahead of a planned five-centre nationwide trial, the Indian Council of Medical Research (ICMR) has approved a special project at the AIIMS Trauma Centre in New Delhi where stem cell therapy will be conducted on complete paraplegics and quadriplegics to try and revive limb function.

A similar trial will be conducted at the Indian Spinal Injuries Centre (ISIC) in Vasant Kunj, south-west Delhi where 21 patients have already been registered. This project too has been approved by the ICMR.

Senior ICMR scientists from the apex committee to monitor stem cell research said the five-centre trial will be coordinated from ISIC and is in the final stages of approval.

This will be the first national ICMR trial of autologous bone marrow stem cell transplant on complete quadriplegics and paraplegics. We are finalising the number of patients. The ISIC will be the coordinating centre. The next meeting has been scheduled for December 4, a senior scientist said.

An autologous stem cell transplantation is a procedure in which stem cells are removed, stored and returned to the same person.

For its project, the AIIMS Trauma Centre has registered eight patients. They will be injected with stem cells from their own bone marrow to see if the damaged neurological function can be regenerated. Doctors have cautioned that earlier trials on incomplete quadriplegics and paraplegics have not suggested significant clinical improvement.

Dr Deepak Aggarwal, associate professor of neurosurgery at the AIIMS Trauma Centre who is coordinating the study, said: We have necessary clearances from our internal ethics committee and the national apex committee for stem cell research and therapy which has members from the ICMR and Department of Biotechnology.

... contd.

Read the original:
Two Delhi centres ready to try stem cell therapy on paraplegics

SAN DIEGO, Nov. 27, 2012 /PRNewswire/ -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the initiation of a randomized, controlled, Phase 2 multi-center study of its investigational hematopoietic stem cell therapy, ProHema, in adult patients undergoing double umbilical cord blood transplantation (dUCBT) for hematologic malignancy. The advancement of ProHema into later-stage development builds upon positive results from a Phase 1b single-center study, interactions with the U.S. Food and Drug Administration and refinements to the product manufacturing process. The previously completed Phase 1b study achieved its primary objective of demonstrating safety and tolerability. The study also established early clinical proof-of-concept trends of accelerated neutrophil recovery, improved 100-day survival and low rates of graft-versus-host disease were evident, and durable and preferential reconstitution with ProHema occurred in 10 of 12 evaluable patients. ProHema is produced through a proprietary, two-hour, ex vivo modulation process, which has been shown to significantly activate key biological pathways involved in hematopoietic stem cell homing, proliferation and survival in preclinical models.

"Allogeneic umbilical cord blood transplantation holds great promise as a potentially curative treatment for children and adults with hematologic malignancies and many other life-threatening, non-malignant disorders," said Christian Weyer, M.D., M.A.S., President and Chief Executive Officer of Fate Therapeutics. "ProHema is being developed with the intent to improve outcomes in patients undergoing cord blood transplantation by facilitating both accelerated engraftment and durable reconstitution using a simple, point-of-care, ex vivo modulation process. The initiation of Phase 2 marks an important milestone for the company and brings us one step closer towards achieving this objective."

The Phase 2 study is expected to enroll at least 45 adult patients undergoing dUCBT for the treatment of hematologic malignancies. Patients will be randomized, with a ratio of 2:1, to receive either ProHema plus an unmanipulated cord blood unit or two unmanipulated cord blood units. The study will evaluate time to neutrophil and platelet recovery, incidence of serious infections and graft-versus-host disease, 100-day mortality and relative dominance of ProHema over the unmanipulated cord in contributing to reconstitution. Results are expected in 2013.

"The preclinical and clinical data obtained to date suggest that ProHema may address several of the unmet medical needs in the evolving field of hematopoietic stem cell transplantation," said Steven Devine, M.D., Professor of Medicine and Program Director of the Blood and Marrow Transplant Program at the Ohio State University and a principal investigator of the Phase 2 clinical study. "While further investigation is required, an intervention that enables early and durable reconstitution of the best-HLA-matched cord blood unit has the potential to improve patient outcomes and substantially enhance the therapeutic value proposition of cord blood transplant."

About ProHema

ProHema is an innovative cord blood-derived cell therapy containing pharmacologically-modulated hematopoietic stem cells (HSCs). ProHema is produced through a proprietary, two-hour, ex vivo cell modulation process that results in rapid activation of key biological pathways involved in homing, proliferation and survival of HSCs. In preclinical testing, ProHema has demonstrated the potential to accelerate engraftment and to drive durable hematopoietic reconstitution, without the need for multi-week expansion protocols. In an initial Phase 1b study in adult patients with hematologic malignancies undergoing double umbilical cord blood transplant (dUCBT), the median time to neutrophil recovery (> 500 cells/microliter) with ProHema was 17.5 days, which compares favorably to historical norms for patients undergoing dUCBT. In that study, ProHema provided the dominant source of hematopoiesis in 10 of 12 evaluable subjects, suggesting that treatment with ProHema may accelerate engraftment and drive durable and preferential reconstitution.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators. The Company's first clinical program, ProHema, is an innovative cord blood-derived cell therapy containing ex vivo pharmacologically-modulated hematopoietic stem cells and is being developed to improve hematopoietic reconstitution in patients undergoing stem cell transplant. In addition, Fate Therapeutics has preclinical programs of novel in vivo stem cell modulators for skeletal muscle regeneration and hearing restoration. To advance its discovery and development efforts, the Company applies its award-winning, proprietary, induced pluripotent stem cell technology to generate rare cell populations and model disease. Fate Therapeutics is headquartered in San Diego, CA, with a subsidiary in Ottawa, Canada. For more information, please visit http://www.fatetherapeutics.com.

Original post:
Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies

NEW YORK, Nov. 26, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy industry, today announced that Company management has been invited to present at the Piper Jaffray 24th Annual Healthcare Conference.

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information on NeoStem, please visit http://www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Here is the original post:
NeoStem to Present at Piper Jaffray 24th Annual Healthcare Conference

Public release date: 27-Nov-2012 [ | E-mail | Share ]

Contact: Robert Miranda cogcomm@aol.com Cell Transplantation Center of Excellence for Aging and Brain Repair

Putnam Valley, NY. (Nov. 27, 2012) A study published in the current issue of Cell Transplantation (21:8), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/, has found that when mesenchymal cells derived from skeletal muscle (SM-MSCs) or adipose tissue (ADSCs) were injected into the heart muscle (myocardium) of separate groups of laboratory rats that had suffered a myocardial infarction, rats in both groups experienced significantly improved left ventricle function and smaller infarct size after cell therapy.

The study, carried out by researchers at Oslo University Hospital and the Norwegian Center for Stem cell Research, Oslo University, sought to determine if MSCs from different organs would result in different functional outcomes.

"Despite advances in revascularization and medical therapy, acute myocardial infarction (AMI) and heart failure are still important causes of morbidity and mortality in industrialized countries," said study co-author Dr. Jan E. Brinchmann of the Norwegian center for Stem Cell Research at Oslo University Hospital, Oslo. "AMI leads to a permanent loss of contractile elements in the heart and the formation of fibrous scarring. Regeneration of contractile myocardium has been a target of cell therapy for more than a decade."

According to Dr. Brinchmann, MSCs tolerate hypoxia, secrete angiogenic factors and have been shown to improve vascularization; thus, they have properties suggesting that they may beneficially impact AMI, chronic heart failure and angina pectoris after cell transplantation. Following injection into the "border zone" and infarct area of immunodeficient rats one week after induced myocardial infarction, the researchers used echocardiography to measure myocardial function and other analyses to measure the size of scaring, density of blood vessels in the scar, and the health of myocardial tissues.

"Our results showed that intramyocardial injection of both ADSCs and SM-MSCs one week after AMI led to a substantial decrease in infarct size and a significant improvement in left ventricle function when compared with injections of cell culture medium alone," concluded the authors. "There was a trend toward better functional improvement in the SM-MSC group when compared to the ADSC group, but this did not reach significance."

They concluded that many questions remain unanswered, including the question of whether MSCs isolated from different organisms could result in different functional outcomes. Other unanswered questions relate to the optimal time delay between the onset of myocardial infarction and injection of MSCs. These cells do, however, still appear to be "a potentially interesting adjuvant treatment modality for selected patients following acute myocardial infarction," they concluded.

###

Contact: Dr. Jan E. Brinchmann, Norwegian Center for Stem Cell Research, Institute of Basic Medical Sciences, Oslo University Hospital Rikshospitalet and University of Oslo, PO Box 1121 Blindern 0317 Oslo, Norway. Tel. +42-22-84-04-89 Fax. +42-22- 85-10-58 Email: jan.brinchmann@rr.research.no

See the original post here:
Study suggests different organ-derived stem cell injections improve heart function

PHILADELPHIA, Nov. 26, 2012 /PRNewswire/ --RRY Publications LLC today announced that the use of stem cell therapies in 2012 significantly exceeded forecasts which were originally presented at the February 2012 New York Stem Cell Summit. Said Robin Young, stem cell industry analyst and host of the New York meeting: "The range and scope of stem cell therapeutic use in the United States grew much faster than we'd forecasted earlier this year. Virtually all of the increases we're seeing are for adult stem cell therapies and, in particular, the use by physicians of both allograft and autologous stem cell products. It would not be an exaggeration to call this unexpected and remarkable growth."

Mr. Young's revised forecast of stem cell commercialization revenues for 2013-2020 will be presented at the February meeting in New York.

The companies, scientists and physicians that are at the forefront of this remarkable increase in stem cell therapeutic use will be presenting at the 8th Annual New York Stem Cell Summit. Listed below is the preliminary lineup of presenters for the 8th Annual Stem Cell Summit.

The Stem Cell Summit, an intensive one-day event, allows attendees to learn about the latest developments in the stem cell marketplace, evaluate the groundbreaking stem cell products physicians are using today, and discover the growing market potential in terms of revenues. For 2013, the Summit will feature 30+ presenters, a research review and debate session, and a special track on expanding the range of stem cell therapies.

The 8th Annual Stem Cell Summit will take place on Feb. 19, 2013, at Bridgewaters in the heart of New York City's historic South Street Seaport. The preliminary roster of companies featured will include representatives from 2012 presenters and new 2013 presenters.

Aastrom Biosciences, Inc.

Advanced Cell Technology

Aldagen, Inc.

AllCells, LLC.

Aruna Biomedical, Inc.

Follow this link:
Dramatic Rise in Stem Cell Therapy Use in 2012

Introducing Stem Cell Therapy Using Oral Placenta Stem Cells | Stem Cell Malaysia
stemcellmalaysia.com Stem cell therapy can take on various forms and choices. Due to the advent of technology, stem cell therapy using oral placenta stem cells is now available. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:3 1ratingsTime:05:23More inScience Technology

Continue reading here:
Introducing Stem Cell Therapy Using Oral Placenta Stem Cells | Stem Cell Malaysia - Video

Perrin 410 Animal Hospital Stem Cell Therapy
From:perrin410Views:0 0ratingsTime:09:58More inPets Animals

Go here to read the rest:
Perrin 410 Animal Hospital Stem Cell Therapy - Video

November 25, 2012 12:54

Former bassist is said to be still in a "partially conscious state" four years on from car accident.

Photo: Tom Oxley/NME

Former Deftones bassist Chi Cheng's family are considering stem cell therapy to aid his recovery from a car accident which put him in a coma in 2008.

Cheng is said to be in a "partially conscious state" and is unable to speak, although he can move his legs on command. The bassist has been in and out of hospitals over the past four years and only got home to recover in June this year.

Now, according to Revolver Magazine, the family is considering alternative therapy in order to speed up Cheng's recovery, as they say the last few months have been a struggle for him.

His brother, Ming Cheng, said: "Once his health gets a little better, we'll start looking into other options...but they don't even do it (stem cell therapy) in the US yet.

"It's a miracle he's still with us," he added. "He's alive and kicking and he's fighting, and I think there's a reason for it. I'm hoping there's a light at the end of the tunnel for Chi."

Deftones released their new album 'Koi No Yokan' on November 12. You can stream the new record, which features 'Entomb (Dazzle)', 'Swerve City', 'Graphic Nature', 'Goon Squad' and 'Leathers', below.

The band tour the UK in 2013. They will play five dates, kicking off at Glasgow's Barrowland on February 15, before heading to Nottingham, Manchester, Birmingham and finishing at London's 02 Brixton Academy (20).

View post:
Deftones' Chi Cheng's family consider stem cell therapy to aid recovery

Daily Mail

Nature Biotechnology Study Highlights New Myelin Specific Approach to Treat ... The Herald | HeraldOnline.com SARATOGA, Calif. — The Myelin Repair Foundation (MRF) today announced the results of a new peer-reviewed research study published in Nature Biotechnology highlighting a targeted, novel approach for multiple sclerosis (MS). By utilizing the Myelin ... Nanoparticles deliver antigen to trick the immune system in MSFierceDrugDelivery MS: Nanoparticle Discovery May Halt MS Without Total Immune System ...Guardian Express Nanoparticles Show Potential for Treating MSCBS 47 all 68 news articles »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNErhLSVVXGN3nY6iYOnxa7W-b-7lA&url=http://www.heraldonline.com/2012/11/19/4426106/nature-biotechnology-study-highlights.html

China Daily

Biotechnology organization sees IP rights essential China Daily "A patent often brings far greater value than one could ever imagine," said Dr Terence L.T. Lau, chief operating officer and general manager of Hong Kong Biotechnology Organization (HKBIO), which innovates the patented biotech product - H5 series of ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEOdlxI8xurAY3bXNV_hXzfJx-45A&url=http://www.chinadaily.com.cn/business/2012-11/20/content_15945771.htm

The California stem cell agency and
StemCells, Inc., are still trying to reach agreement on a deal in
which the company would receive $40 million from the state's
taxpayer-funded research effort.

“We are still in talks with them over
the terms of the funding. Hopefully, we'll have an agreement soon.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/MeZfo2qdxDQ/california-stem-cell-agency-still-in.html

In nine days, the California stem cell
agency plans to take another crack at finding ways to curb its
free-wheeling appeal process involving scientists whose applications
for millions have been rejected by reviewers.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/5vUXCLMoJz8/texas-flaps-looms-over-california-stem.html

Claire Pomeroy, one of the longtime
members of the governing board of the $3 billion California stem cell agency,
will be leaving her position at UC Davis and the stem cell board next
June.

Claire Pomeroy UC Davis photo

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/aS-PH9NtXbA/pomeroy-moving-on-will-leave-stem-cell.html

A UC Davis stem cell researcher-blogger has announced a “stem cell person of the year” award
complete with a $1,000 cash prize that he is putting up himself.

Paul Knoepfler UC Davis photo

He said he wanted to go beyond “old
fashioned awards” given by “stodgy committees.” Knoepfler said he
is seeking to recognize that stem cell research is “transcending the
lab.”

“The criteria are that the person
made a truly outstanding difference in the stem cell field for 2012.
The winner could be a scientist, a patient advocate, someone in
industry, a student, a physician…really anyone who has made the
field better. For non-scientist nominees I’m particularly
interested in those who took personal risks or gave of themselves to
help others. For scientists I am looking for outstanding scientific
achievement and in particular out-of-the-box thinking. Folks in any
country are eligible.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/D_njqx1jc1U/the-knoepfler-award-recognizing-risk.html

The California stem cell agency
published an article online last week concerning the hESC clinical
trial that Geron abandoned last year, dealing mainly with one of the
participants in the program.

“They (BioTime) would need to apply
for a loan if they want CIRM to financially support the continued
trial.”

“Katie told me that it would be
impossible not to hope that a trial would help her, but that by the
time she made the decision to participate she knew she was doing it
to further science, not necessarily to further her own recovery. She
told the audience, 'I was part of something that was bigger than me,
and bigger than all of you.'”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/VlS7kYH6oy4/california-stem-cell-agency-blogs-on.html

The California stem cell agency has
posted the dates for meetings of its board of directors for 2013
with most of the sessions scheduled for the San Francisco Bay Area.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/YJowRDshtEY/researcher-alert-keeping-tabs-on-stem.html

Introduction To Stem Cell Therapy For Parkinson #39;s And Alzheimer #39;s Diseases | Stem Cell Malaysia
stemcellmalaysia.com Stem cell therapy projects so much potential and hope for patients of different illnesses. This is due to the unique characteristics of stem cells. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:3 1ratingsTime:03:51More inPeople Blogs

Here is the original post:
Introduction To Stem Cell Therapy For Parkinson's And Alzheimer's Diseases | Stem Cell Malaysia - Video

24K Gold
Get the best offer here redirect.viglink.com?key=f341fd9454fc162be8b38d504acbd4e1 out=http%3A%2F%2Fwww%2Eamazon%2Ecom%2Fdp%2FB0079QOQRG Product Description 24K Gold Experience the Anti-Aging Power of the New Generation 24K Nano Gold Stem Cell Therapy Mask. This excellent product by BeautyMedica Lab offers an innovative Transdermal Delivery System with a unique blend of transforming growth factors (TGF), amino acids, antioxidants and peptides.Sheet form of the mask makes it extremely easy to apply to the face and allowing the ingredients to be absorbed into the skin slowly melting under body temperature. The Mask was formulated to Re-activate stem cells and stimulate new skin development. Increase collagen production and elastin synthesis. Minimize appearance of fine lines and wrinkles. Enhance moisture with Y-PGA and refine skin structure. Whiten the skin and reduce melanin. Restore youthful healthy looking skin and creates radiant skin appearance.For more info, please visit 24K Gold Mask presentation video by Beauty Medical Laboratorys - http://www.youtube.comFrom:Bernarda YooViews:3 0ratingsTime:00:58More inScience Technology

View post:
24K Gold - Video

Biologic Cell
Get the best offer here redirect.viglink.com?key=f341fd9454fc162be8b38d504acbd4e1 out=http%3A%2F%2Fwww%2Eamazon%2Ecom%2Fdp%2FB0083UMZOI Product Description Biologic Cell Re-Activate your stem cells to make wrinkles disappear! Set of 4 - 1 oz. jars.Stem Cell Therapy is the newest bio-active topical cream that actually stimulates your own skin stem cells to grow smooth, supple, firm new skin.Three powerful ingredients, Phyko-AI-PF (increases skin production by 57%), Mitostime (re-activates stem cells), and Seractin (a youth compound targeted at decreasing your deepest wrinkles) all work together to help you turn back the clock.Results start to appear within 2 weeks of regular use.From:Lilliam FogleViews:2 0ratingsTime:00:58More inNews Politics

Read the original post:
Biologic Cell - Video

Fifty50 24K Gold
Buy from Amazon US redirect.viglink.com?key=f341fd9454fc162be8b38d504acbd4e1 out=http%3A%2F%2Fwww%2Eamazon%2Ecom%2Fexec%2Fobidos%2FASIN%2FB007927WAS%2Fhealth%5Fhope%2D20 Product Description Fifty50 24K Gold Experience the Anti-Aging Power of the New Generation 24K Nano Gold Stem Cell Therapy Mask. This excellent product by BeautyMedica Lab offers an innovative Transdermal Delivery System with a unique blend of transforming growth factors (TGF), amino acids, antioxidants and peptides.Sheet form of the mask makes it extremely easy to apply to the face and allowing the ingredients to be absorbed into the skin slowly melting under body temperature. The Mask was formulated to Re-activate stem cells and stimulate new skin development. Increase collagen production and elastin synthesis. Minimize appearance of fine lines and wrinkles. Enhance moisture with Y-PGA and refine skin structure. Whiten the skin and reduce melanin. Restore youthful healthy looking skin and creates radiant skin appearance.For more info, please visit 24K Gold Mask presentation video by Beauty Medical Laboratorys - http://www.youtube.com Disclaimer: Hope is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon. Amazon and the Amazon logo are trademarks of Amazon, Inc. or its affiliates.From:Mi WadsworthViews:0 0ratingsTime:00:58More inPeople Blogs

See the article here:
Fifty50 24K Gold - Video